6 Jan 2009 14:11
Immediate Release: Tuesday 6th January 2009
Toumaz Holdings Limited (`Toumaz Holdings', the `Company' or the `Group') Statement Re Share Price Movement
Toumaz Holdings notes the recent increase in the Company's share price, which it attributes to recent press speculation. The Group confirms it does not anticipate announcing a joint venture deal in the immediate future.
In line with recent announcements made by the Group, the push to commercialisation of its investments continues into 2009. Toumaz Technology Limited (`Toumaz Technology') has recently secured two significant agreements. As part of the previously announced engagement with Cardinal Health Inc., the first of a series of pilot studies on the performance of the key Sensiumâ„¢ technology has been approved by ethics and the Medicines and Healthcare products Regulatory Agency (`MHRA') and is about to begin in a UK. In addition, Texas Instruments Inc. has accepted Sensiumâ„¢ as a fully qualified product and sales will begin shortly in the medical device sector.
For further information please contact: Guy Spelman Toumaz Holdings Limited Tel: +44 7767 338 967 Rose Herbert/ Charles Cunningham/ Sam Smith FinnCap Tel: 020 7600 1658 Vikki Krause Hansard Group Tel: +44 207 245 1100
vendor